argenx

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

Shares of argenx (NASDAQ:ARGX) fell 3.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 60.08% year over year to ($4.21), which missed the estimate of ($3.19).

argenx: Q4 Earnings Insights

- Biologics License Application (BLA) for IV efgartigimod accepted for review by U.S. Food and Drug Administration (FDA) for generalized myasthenia gravis (gMG)

argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update

The FDA has accepted for review Argenx SE's (NASDAQ: ARGX) marketing application seeking approval for intravenous (IV) efgartigimod, for the treatment of generalized myasthenia gravis (gMG). Myasthenia gravis is a neuromuscular disorder primarily characterized by muscle weakness and muscle fatigue.

Argenx's Efgartigimod US Application In Neuromuscular Disorder Accepted For Review

February 25, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on March 4, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its full year 2020 financial results and provide a fourth quarter business update.

argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021

Regulated information — Inside information

argenx raises $1.0 billion in gross proceeds in a global offering

-No observed elevation of cholesterol markers related to treatment with efgartigimod

argenx Issues Statement Concerning Efgartigimod

argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis

EyePoint Pharmaceuticals

Gilead Sciences

Gracell Biotechnologies

Inovio Pharmaceuticals

Eli Lilly

Paratek Pharma

Zai Lab Ltd.

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up to $175 million in upfront and near-term payments.

Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOs

Breda, the Netherlands – Jan. 8, 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced its 2021 corporate priorities and highlighted recent achievements from its late-stage immunology pipeline driven by its FcRn antagonist, efgartigimod. Additionally, the Company announced interim data from the Phase 2 CULMINATE trial of cusatuzumab in development with Cilag GmbH International, an affiliate of Janssen, and provided financial guidance for 2021.

argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline

January 4, 2021 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 8:20 a.m. ET.

argenx to Present at 39th Annual J.P. Morgan Healthcare Conference

BREDA, the Netherlands and GHENT, Belgium, Nov. 17, 2020 /PRNewswire/ -- argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced the release of a new docuseries, A...

argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience

November 9, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that management will participate in several upcoming investor conferences:

argenx to Participate in Upcoming Virtual Investor Conferences

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q3 2020 Results - Earnings Call Transcript

Shares of argenx (NASDAQ:ARGX) decreased 6.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 450.00% year over year to ($3.96), which missed the estimate of ($2.81).

Recap: argenx Q3 Earnings

- Biologics License Application (BLA) for efgartigimod in generalized myasthenia gravis (gMG) on track to be submitted to U.S. Food and Drug Administration (FDA) by end of 2020 -

argenx Reports Third Quarter 2020 Financial Results and Provides Business Update

October 15, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, October 22, 2020 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its third quarter 2020 financial results and provide a business update.

argenx to Report Third Quarter 2020 Financial Results and Business Update on October 22, 2020

Argenx: Competitive Positioning In The GMG Space

argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships

argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session

August 4, 2020    Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 12:35 p.m. ET.

argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2020 Results - Earnings Call Transcript

July 30, 2020    Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced its half year 2020 financial results and provided a second quarter business update and outlook for the remainder of the year.

argenx reports half year 2020 financial results and provides second quarter business update

On Thursday, July 30, argenx (NASDAQ: ARGX) will release its latest earnings report.

Earnings Preview: argenx

argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

News for argenx Stock (ARGX)